Related Experiment Video
Updated: Jun 4, 2026
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Obinutuzumab is effective for refractory primary membranous nephropathy
Na Zhao1,2, Ping Chen3,4, Juan Chen3,4
1Department of Nephrology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, No. 16766, Jingshi Road, Jinan, Shandong, 250014, PR China. orange_3420@163.com.
Obinutuzumab (OBZ) shows high efficacy in treating refractory membranous nephropathy, achieving an 89.3% overall response rate. This anti-CD20 therapy is well-tolerated, offering a promising option for patients with this autoimmune kidney disease.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Primary membranous nephropathy is an autoimmune kidney disease linked to anti-phospholipase A2 receptor (PLA2R) antibodies.
- Anti-CD20 monoclonal antibodies are a recommended treatment, with obinutuzumab (OBZ) showing potential.
- Limited studies exist on OBZ efficacy in refractory cases.
Purpose of the Study:
- To evaluate the therapeutic outcomes of obinutuzumab (OBZ) in patients with refractory membranous nephropathy.
- To assess OBZ's effectiveness in patients resistant to or relapsed after standard treatments.
Main Methods:
- Retrospective analysis of 28 refractory membranous nephropathy patients treated with OBZ.
- Minimum follow-up of 3 months; patients previously failed glucocorticoid/cyclophosphamide, calcineurin inhibitors, or rituximab.
- Primary outcomes: complete remission (CR) or partial remission (PR) of proteinuria.
Main Results:
- An 89.3% overall response rate (32.1% CR, 57.2% PR) was observed.
- Significant reduction in proteinuria and increase in serum albumin levels.
- Rapid B-cell depletion and decreased anti-PLA2R antibody levels were noted; no serious adverse events.
Conclusions:
- Obinutuzumab (OBZ) is effective and well-tolerated in refractory membranous nephropathy.
- OBZ demonstrates potential as a therapeutic option for this patient group.
- Further validation in larger, multi-center studies is warranted.
